New Cancer Blood Test May Bolster Mesothelioma Diagnostic Tools
A new cancer blood test may make boost the accuracy of current screening tools and allow doctors to detect malignant mesothelioma and other hard-to-find cancers earlier. The test is called a multi-cancer early detection (MCED) test. The US company Grail developed it and researchers at the Cleveland Clinic tested it on more than 3,500 patients. They found that it correctly identified cancer in more than half of cases. The test was even more accurate in rare cancer types for which no screening test is available. Malignant mesothelioma was not specifically mentioned in the report. But it is an extremely rare cancer. The method used by the new cancer blood test suggests that it could be useful for finding mesothelioma, too. … Continue reading New Cancer Blood Test May Bolster Mesothelioma Diagnostic Tools
BAP1 Not the Only Gene to Raise Mesothelioma Risk
A new study is further evidence that a mutation on the BAP1 gene is not the only genetic anomaly to raise mesothelioma risk. Scientists at Philadelphia’s Fox Chase Cancer Center along with a team of international researchers recently published a study of 13 malignant mesothelioma patients. All of these patients had close relatives who also had cancer. This suggested that something in their genetic makeup might raise mesothelioma risk. Previous research suggests one gene that makes people more susceptible to mesothelioma is BAP1. People with a mutation on this gene are more likely to receive a mesothelioma diagnosis. They are also more susceptible to several other conditions. But the people in the new study were chosen because none of them … Continue reading BAP1 Not the Only Gene to Raise Mesothelioma Risk
Japanese Researchers Discover ‘Novel Diagnostic Marker’ for Mesothelioma
A protein called CDLN15 could be a novel diagnostic marker for malignant pleural mesothelioma, allowing doctors to pinpoint asbestos cancer earlier and boost the odds of survival. That is the message from a recently published Japanese study. Pleural mesothelioma is notoriously difficult to diagnose. It rarely causes any symptoms at all until it is in a late stage. When the symptoms do show up, they are easy to confuse with other illnesses. Earlier diagnosis of pleural mesothelioma depends on finding things that set it apart from other diseases. This novel diagnostic marker could serve as a red flag for this rare but deadly cancer. CDLN15 as a Novel Diagnostic Marker CDLN15 stands for claudin-15. Claudins are a family of proteins … Continue reading Japanese Researchers Discover ‘Novel Diagnostic Marker’ for Mesothelioma
Artificial Intelligence Improves Mesothelioma Diagnosis, Study Finds
There is more evidence that artificial intelligence may have a role to play in helping doctors diagnose deadly malignant mesothelioma earlier. A study conducted at Japan’s Hyogo College of Medicine used past patient records to test a deep convolutional neural network (CDNN). This is a complex computer program designed to evaluate diagnostic criteria. Pleural mesothelioma is a difficult cancer for doctors to diagnose. Artificial intelligence can help by quickly comparing diagnostic data to hundreds of past cases. In the Japanese study, the AI produced the most accurate mesothelioma diagnoses when combined with all of the available patient data. The Challenge of Diagnosing Mesothelioma Mesothelioma tumors grow on the membranes around internal organs. They usually come from past exposure to asbestos. … Continue reading Artificial Intelligence Improves Mesothelioma Diagnosis, Study Finds
Breath Test Could Predict Mesothelioma Immunotherapy Response
New research shows a breath test called an eNose might help doctors determine which mesothelioma patients are most likely to respond to immunotherapy. Immunotherapy is one of the most promising new approaches to malignant mesothelioma. But not every patient responds. A new Dutch study suggests that biomarkers in a patient’s exhaled breath may be indicators of immunotherapy response. The eNose breath test can identify those biomarkers quickly and easily. The technology might make it easier to decide on the best mesothelioma treatment. Immunotherapy for Malignant Mesothelioma Pleural mesothelioma is a rare but deadly cancer of the lung lining. Until last year, chemotherapy with Alimta (pemetrexed) was the only FDA-approved systemic treatment. In 2020, the FDA approved a combination of immunotherapy … Continue reading Breath Test Could Predict Mesothelioma Immunotherapy Response
Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival
Mesothelioma patients with higher levels of the PD-L1 protein in their tumor cells have worse overall survival compared to those with lower levels. But that may not be true for patients who have immunotherapy. That news comes from a new European study of more than 200 patients. PD-L1 and its partner protein PD-1 (found in immune system cells) are popular targets for new immunotherapy drugs. But the new study aimed to find out if they impact mesothelioma survival independently of immunotherapy. The team concluded the PD-L1 protein may shorten lifespan. PD-1 does not seem to have the same effect. Pleural Mesothelioma and the PD-L1 Protein Pleural mesothelioma is an intractable cancer of the lung lining. It often leads to poor … Continue reading Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival
Immunohistochemical Staining and Sarcomatoid Mesothelioma: Beyond the Lab
When it comes to understanding individual cases of sarcomatoid mesothelioma, doctors should not rely too heavily on immunohistochemical staining. That conclusion comes from mesothelioma researchers at MD Anderson Cancer Center in Texas. The researchers just released a new study focused on this rare mesothelioma subtype. A patient’s subtype has an impact on what kind of treatment could work best for them. Sarcomatoid mesothelioma is usually less responsive to chemotherapy. Immunohistochemical staining is a pathology technique. It is the main way that doctors tell the difference between mesothelioma subtypes. But the MD Anderson report suggests that not all cases of sarcomatoid mesothelioma are created equal. The researchers say it is important to look beyond the lab findings to understand individual cases. … Continue reading Immunohistochemical Staining and Sarcomatoid Mesothelioma: Beyond the Lab
LA Woman’s Story is a Sobering Reminder to Watch for Signs of Pleural Mesothelioma
The plight of an LA actress who found out she had lung cancer because of a COVID test is a sobering reminder to be aware of the early signs of pleural mesothelioma. The woman’s story was recently featured on the Today Show website. Fifty-nine year old Annabelle Gurwitch is a non-smoker with no known lung cancer risk factors. She and her 23-year-old child decided to get COVID tests after her child came home from college. Although the COVID test was negative, Gurwitch writes that doctors were concerned about her persistent cough. Ongoing cough can be a one of the early signs of pleural mesothelioma, too. An X-ray revealed that Gurwitch was suffering from Stage 4 lung cancer, the most common … Continue reading LA Woman’s Story is a Sobering Reminder to Watch for Signs of Pleural Mesothelioma
Concerning CT Findings and Mesothelioma Prognosis
One of the nation’s top mesothelioma doctors says concerning CT findings may be one of the best ways to predict peritoneal mesothelioma outcomes. Dr. Paul Sugarbaker is with MedStar Washington Hospital Center in Washington, DC. His newly published study compares 11 different concerning CT findings with outcomes in 100 mesothelioma patients. Sugarbaker and his team found that the prognostic value of these 11 CT features is on a par with peritoneal cancer index (PCI) and cytoreduction (CC) score. It means that CT findings could become even more important for mesothelioma treatment planning. CT Scans Reveal Information About Peritoneal Mesothelioma Peritoneal mesothelioma occurs on the lining around the abdomen. It is an aggressive and hard-to-treat cancer caused by exposure to asbestos. … Continue reading Concerning CT Findings and Mesothelioma Prognosis
Waiting for Medicare Coverage Could Impact Mesothelioma Survival
People who suspect they may have cancer but wait to get a diagnosis until they are eligible for Medicare coverage could negatively impact their ability to survive mesothelioma. That is the message from a new Stanford study. The study suggests that many people wait until they are 65 to seek cancer care. For people with a fast-growing cancer like mesothelioma, delaying diagnosis by waiting for Medicare coverage could have devastating consequences. Early Mesothelioma Diagnosis Key to Survival Malignant pleural mesothelioma is a form of lung cancer caused by exposure to asbestos. It is one of the most deadly types of cancer. Like most cancers, the chances of surviving mesothelioma are higher the earlier it is diagnosed. But mesothelioma is not … Continue reading Waiting for Medicare Coverage Could Impact Mesothelioma Survival
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!